Solvonis Therapeutics plc

Research Solvonis Therapeutics plc (SVNS) on Bullrun: market cap GBX 13.27M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSVNS
• ExchangeLSE
• CountryUnited Kingdom
• SectorIndustrials
• IndustrySpecialty Industrial Machinery
• CurrencyGBX
• Market capGBX 13.27M
• Financial periodQ4 2024
• Net income-GBP 335.00K
• Free cash flow-GBP 149.00K

Valuation Snapshot

latest market cap is GBX 13.27M.

About Solvonis Therapeutics plc

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder;

Frequently asked questions

What is Solvonis Therapeutics plc's market cap?

Solvonis Therapeutics plc's market capitalization is GBX 13.27M.

What does Solvonis Therapeutics plc do?

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder;